Search

Displaying results 1691 - 1700 of 4288 in total
  1. Drug

    Formebolone

    go.drugbank.com/drugs/DB01569
    IllicitInvestigational

    [A14416] It is also classified by the US Drug Enforcement Administration as Schedule III drug in the Controlled Substances Act.

  2. Drug

    Insulin pork

    go.drugbank.com/drugs/DB00071
    Approved

    Insulin isolated from pig pancreas. Composed of alpha and beta chains, processed from pro-insulin. Forms a hexameric structure.

  3. Drug

    AP1081

    go.drugbank.com/drugs/DB05233
    Experimental

    A transdermal gel containing ethinyl estradiol and norelgestromin being investigated by Antares Pharma for use as a female contraceptive.

  4. Drug

    Sotorasib

    go.drugbank.com/drugs/DB15569
    ApprovedInvestigational

    Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen.

  5. Drug

    Cetrimonium

    go.drugbank.com/drugs/DB01718
    ApprovedInvestigational

    Cetrimonium is a quaternary ammonium cation whose salts are used as antiseptics.

  6. Drug

    Hexestrol

    go.drugbank.com/drugs/DB07931
    ApprovedWithdrawn

    A synthetic estrogen that has been used as a hormonal antineoplastic agent.

  7. Drug

    Alirocumab

    go.drugbank.com/drugs/DB09302
    ApprovedInvestigational

    Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of

  8. Drug

    Gramicidin D

    go.drugbank.com/drugs/DB00027
    ApprovedInvestigational

    Active against most Gram-positive bacteria and some Gram-negative organisms, Gramicidin D is used primarily as a topical antibiotic and is also found in Polysporin ophthalmic solution.

  9. Drug

    Tetrodotoxin

    go.drugbank.com/drugs/DB05232
    Investigational

    Tetrodotoxin is being investigated by Wex Pharmaceuticals for the treatment of chronic and breakthrough pain in advanced cancer patients as well as for the treatment of opioid dependence.

  10. Drug

    Ibandronate

    go.drugbank.com/drugs/DB00710
    ApprovedInvestigational

    [L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.[A203138] Ibandronate was granted FDA approval on 16 May 2003.[L13805]

    Products: ACIDO IBANDRONICO DOC GENERICI